Video Experimental Relacionado
Updated: Sep 9, 2025
10:26
Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
8.5K
Actualización reciente sobre el desarrollo de inhibidores y degradantes de EZH2 para el tratamiento del cáncer
Meiyue Tang1, Ming Gong2, Xiaoliang Liu3
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
European journal of medicinal chemistry
|August 30, 2025
Resumen
Los inhibidores del potenciador del zeste homólogo 2 (EZH2) son cruciales para la terapia del cáncer al bloquear el silenciamiento de genes. Las nuevas estrategias como los inhibidores duales y los degradantes tienen como objetivo mejorar la eficacia y superar la resistencia.
Área de la Ciencia:
- La epigenética
- Biología del cáncer
- Farmacología
Sus antecedentes:
- El potenciador del zeste homólogo 2 (EZH2) es clave en la regulación epigenética, controlando la expresión génica a través de la metilación de las histonas.
- La desregulación de EZH2 está relacionada con varios tipos de cáncer, impulsando la oncogénesis y la progresión tumoral.
- Dirigirse a EZH2 es una estrategia terapéutica prometedora para el cáncer.
Objetivo del estudio:
- Revisar las terapias dirigidas a EZH2 desarrolladas desde 2020.
- Para discutir los avances en los inhibidores y degradantes de EZH2.
- Explorar las direcciones futuras para optimizar los tratamientos contra el cáncer dirigidos a EZH2.
Principales métodos:
- Revisión de la literatura científica sobre las terapias dirigidas al EZH2.
- Análisis de medicamentos aprobados y datos de ensayos clínicos.
- Exploración de estrategias terapéuticas de nueva generación.
Principales resultados:
- Progreso significativo en el desarrollo de inhibidores y degradantes de EZH2.
- Varios agentes dirigidos a EZH2 están aprobados o en ensayos clínicos.
- Las estrategias de próxima generación muestran potencial para mejorar la eficacia y el manejo de la resistencia.
Conclusiones:
- Los inhibidores de EZH2 representan un enfoque vital en el tratamiento del cáncer.
- La investigación en curso se centra en los inhibidores avanzados, los degradantes y las terapias combinadas.
- Las direcciones futuras tienen como objetivo maximizar los beneficios terapéuticos y superar la resistencia al tratamiento.
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K